In breast cancer, amplification or overexpression of ERBB2 is a common event that appears in 15–30% of all specimens [11], and ERBB2 gene amplification and/or overexpression have been associated with a poor clinical outcome [12], [13]. Here, ERBB2 is linked to breast carcinoma.